Numbers on injectable treatments in the Netherlands in 2016

Decates, Tom; Wijs, Linde E.M. de; Nijsten, Tamar; Velthuis, Peter

doi:10.1111/jdv.14877

Cited by 10 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For aesthetic reasons alone, almost 2.7 million dermal fillers have been injected in the United States in 2018, a 50% increase since 2010 1 . A recent study in the Netherlands shows that each year, 1 out of 49 women receive at least one injection treatment 2 …”

Section: Introductionmentioning

confidence: 99%

“…1 A recent study in the Netherlands shows that each year, 1 out of 49 women receive at least one injection treatment. 2 Physicians have different types of dermal fillers at their disposal, consisting either of resorbable or nonresorbable materials. Manufacturers claim that marketed fillers are nontoxic and nonimmunogenic, which are requirements for any biomaterial intended for aesthetic uses.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Increased risk of late‐onset, immune‐mediated, adverse reactions related to dermal fillers in patients bearing HLA‐B 08 and DRB1 03 haplotypes

Decates

Velthuis

Schelke

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Even though manufacturers claim that the dermal fillers are nontoxic and nonimmunogenic, adverse events may occur. Clinically and histologically, most of the late onset adverse events present as an inflammatory response. To assess whether HLA polymorphisms are associated with late‐onset inflammatory adverse events related to dermal fillers. A total of 211 patients were included, of whom 129 experienced late‐onset inflammatory adverse events to different fillers (Inflammation group) and 82 who did not (Reference group). Patients completed a standardized questionnaire and provided a blood sample or oral swap for HLA testing. The study population consisted of 188 (89%) women and 23 (11%) men. The two study groups were similar in the distributions of filler type, location of injecting, allergy, autoimmune disease, gender, age, ethnicity, and smoking status. Of the 211 patients in the sample, 25 had the combination of HLA subtype‐B*08 and HLA subtype‐DRB1*03. This was 16.3% of the inflammatory group and 4.9% of the reference group. This combination of HLA subtypes was associated with an almost 4‐fold increase in the odds of developing immune mediated adverse events (odds ratio = 3.79, 95% CI 1.25‐11.48). Genetic polymorphisms such as HLA combinations may identify patients at risk of developing late onset immune mediated adverse events to dermal fillers.

show abstract

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

Increased risk of late‐onset, immune‐mediated, adverse reactions related to dermal fillers in patients bearing HLA‐B 08 and DRB1 03 haplotypes

Decates

Velthuis

Schelke

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Recently, we calculated the total number of filler treatments performed in the Netherlands in 2016. 7 For this purpose, we searched Google , the Dutch Archive Data Care Register, and membership lists of professional specialty associations to assess the number of doctors performing such treatments and sent them questionnaires to inquire how many filler injections they had conducted in 2016. The response rate was 37% (n = 122).…”

mentioning

confidence: 99%

“…margins: 129,866-147,126). 7 With this information and the knowledge that virtually every patient with an VAE is referred to us, we were able to calculate the incidence of vascular occlusion filler treatments quite accurately.…”

mentioning

confidence: 99%

Incidence of Vascular Obstruction After Filler Injections

Schelke¹,

Decates²,

Kadouch³

et al. 2020

Aesthetic Surgery Journal

View full text Add to dashboard Cite

“…The use of hyaluronic acid gel fillers for rejuvenation of the face has been increasing in popularity over the years. 1,2 This nonsurgical technique with a temporary effect is commonly used in the periocular region to restore volume. Unfortunately, in 11% of the treatments, this so-called "tear trough" with hyaluronic acid gel filler malar edema occurs.…”

Section: Introductionmentioning

confidence: 99%

Unilateral facial edema after filler injection of the lower eyelid

Decates

Spanjer

Saini³

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

The use of hyaluronic acid (HA) gel fillers for rejuvenation of the face has been increasing in popularity over the years. This nonsurgical, temporary technique is commonly used in the periocular region to restore volume. The aim of this study was creating awareness in the potential causes of edema after hyaluronic acid gel filler injections under the eyes. A 32‐year‐old woman presented for a cosmetic consultation to address unilateral swelling of the left check. She states she had an HA filler injected in the tear trough on both sides. Extensive evaluation and ultrasound were performed by physicians of different specialties. Intra‐oral and radiological examination revealed a tooth‐related cause known as apical periodontitis. Removal of this tooth resulted in complete resolution of the patient's presenting symptoms. Familiarity with all the potential causes of adverse events after injections with hyaluronic acid gel fillers accelerates the treatment and healing of the patient with complications. Reporting this case should raise awareness about possible teeth‐related complications.

show abstract

Numbers on injectable treatments in the Netherlands in 2016

Cited by 10 publications

References 0 publications

Increased risk of late‐onset, immune‐mediated, adverse reactions related to dermal fillers in patients bearing HLA‐B 08 and DRB1 03 haplotypes

Increased risk of late‐onset, immune‐mediated, adverse reactions related to dermal fillers in patients bearing HLA‐B 08 and DRB1 03 haplotypes

Incidence of Vascular Obstruction After Filler Injections

Unilateral facial edema after filler injection of the lower eyelid

Contact Info

Product

Resources

About

Numbers on injectable treatments in the Netherlands in 2016

Cited by 10 publications

References 0 publications

Increased risk of late‐onset, immune‐mediated, adverse reactions related to dermal fillers in patients bearing HLA‐B *08 and DRB1 *03 haplotypes

Increased risk of late‐onset, immune‐mediated, adverse reactions related to dermal fillers in patients bearing HLA‐B *08 and DRB1 *03 haplotypes

Incidence of Vascular Obstruction After Filler Injections

Unilateral facial edema after filler injection of the lower eyelid

Contact Info

Product

Resources

About

Increased risk of late‐onset, immune‐mediated, adverse reactions related to dermal fillers in patients bearing HLA‐B 08 and DRB1 03 haplotypes

Increased risk of late‐onset, immune‐mediated, adverse reactions related to dermal fillers in patients bearing HLA‐B 08 and DRB1 03 haplotypes